Monoisoamyl meso-2,3-dimercaptosuccinate as a delayed treatment for mercury removal in rats.
Monoisoamyl meso-2,3-dimercaptosuccinate (Mi-ADMS) was found to be superior to meso-2,3-dimercaptosuccinic acid (DMSA) in decreasing the body burden of 203Hg in rats under conditions of early treatment. In this experiment Mi-ADMS was used as late treatment for mercury removal. Albino rats aged 6 weeks and 7-day-old sucklings received a single intraperitoneal injection of 203Hg (as nitrate). Two weeks later they were treated with DMSA or Mi-ADMS (0.25 mmole/kg bw) on two consecutive days. The radioactivity in the carcass (whole body after removal of the gastrointestinal tract), liver, kidneys and brain was determined by solid crystal gamma scintillation counting six days after chelation therapy administration (3 weeks after 203Hg application). Both chelators reduced the body burden of mercury compared to controls. The effect of Mi-ADMS was superior to DMSA treatment in older rats for decreasing carcass and kidney retention, and in suckling rats for decreasing carcass, liver, and kidney retention. They were equally effective in decreasing brain retention in older rats and had no effect on brain retention in sucklings. The efficiency of Mi-ADMS in reducing the body burden of mercury was generally higher than the efficiency of the DMSA treatment. Therefore, Mi-ADMS deserves further attention as a late treatment for mercury removal.
Kostial
K
K
Department of Mineral Metabolism, University of Zagreb, Croatia.
Kargacin
B
B
Blanusa
M
M
Piasek
M
M
Jones
M M
MM
Singh
P K
PK
D000375:Aging / Q000378:metabolism; D000818:Animals; D000833:Animals, Suckling; D015913:Chelation Therapy; D008630:Mercury Poisoning / Q000188:drug therapy* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D004113:Succimer / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013997:Time Factors
C091888:monoisoamyl-2,3-dimercaptosuccinate; D004113:Succimer